Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 3,229 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Active, not recruiting Phase 3 Interventional

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404
View directory record Official record
Conditions
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 8:16 PM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Low Dose Dexmedetomidine as a Postoperative Pain Adjunct

NCT06067893
View directory record Official record
Conditions
Spinal Fusion, Adolescent Idiopathic Scoliosis
Interventions
Dexmedetomidine, Normal Saline
Drug
Lead sponsor
Nichole Doyle
Other
Eligibility
10 Years to 21 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 2 Interventional

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

NCT01703533
View directory record Official record
Conditions
Rett Syndrome
Interventions
NNZ-2566, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Saint Paul, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 8:16 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

NCT03597347
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
Interventions
Molgramostim nebulizer solution, PARI eFlow nebulizer system
Drug · Device
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Silver Diamine Fluoride Pilot Study (SDF)

NCT02591147
View directory record Official record
Conditions
Dental Caries
Interventions
Silver Diamine Fluoride 38%, Group 2 (Placebo)
Device
Lead sponsor
Justine Kolker
Other
Eligibility
21 Years to 64 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Multimodal Pain Management for Cesarean Delivery

NCT02922985
View directory record Official record
Conditions
Pain
Interventions
Intravenous acetominophen, Ketorolac, intramuscular, Bupivacaine, subcutaneous, Normal saline
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 25, 2026, 8:16 PM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
Clemizole HCl, Placebo
Drug
Lead sponsor
Epygenix
Industry
Eligibility
2 Years to 55 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Little Rock, Arkansas • Orange, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Clinical Outcomes Between GentleWave® and Biolase®

NCT05555043
View directory record Official record
Conditions
Endodontic Disease, Periapical Diseases, Periapical Periodontitis, Root Canal Infection
Interventions
Irrisafe ip, GentleWave System, Waterlase iPlus
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
14 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults

NCT00333398
View directory record Official record
Conditions
Influenza
Interventions
CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free, CSL Trivalent Inactivated Influenza Vaccine with Thimerosal, Placebo with Thimerosal
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
10
States / cities
Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

21 Day Cumulative Skin Irritation of RUT058-60

NCT02198963
View directory record Official record
Conditions
Irritation/Irritant
Interventions
Hypochlorous acid solution 106 mg/L, 0.1% (w/v) Sodium Lauryl Sulfate, 0.9% Physiological Saline, USP
Drug
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 25, 2026, 8:16 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

NCT05775848
View directory record Official record
Conditions
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Interventions
BBP-418 (ribitol), Placebo
Drug · Other
Lead sponsor
ML Bio Solutions, Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Little Rock, Arkansas • Irvine, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Not applicable Interventional

Nurtured in Nature

NCT04146025
View directory record Official record
Conditions
Postpartum Depression, Pregnancy Related, Environmental Exposure
Interventions
Nature Coach Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

NCT05696080
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V116, Placebo, PCV15, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
8
States / cities
Mesa, Arizona • Hialeah, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

NCT03737851
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
elezanumab, placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Accuracy of Current Techniques in Quantifying Ketone Levels

NCT06909331
View directory record Official record
Conditions
Placebo - Control, Exogenous Ketone Salt
Interventions
Exogenous ketone salt, Placebo drink solution
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 4 Interventional Results available

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

NCT04677959
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
46
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

NCT05525546
View directory record Official record
Conditions
Risk Reduction
Interventions
Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 25, 2026, 8:16 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Controlling Rapid Atrial Fibrillation With Dexmedetomidine

NCT04042727
View directory record Official record
Conditions
Rapid Atrial Fibrillation, Heart Rate Control
Interventions
Dexmedetomidine Hydrochloride, Normal Saline
Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 25, 2026, 8:16 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

NCT00608231
View directory record Official record
Conditions
Parkinson's Disease, Essential Tremor, Dystonia
Interventions
Dexmedetomidine Hydrochloride Infusion, Normal Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

NCT00513240
View directory record Official record
Conditions
Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Aortic Arch Hypoplasia or Interruption
Interventions
Erythropoetin, Normal saline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 30 Days
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 3 Interventional Results available

Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury

NCT05171673
View directory record Official record
Conditions
Soft Tissue Injuries
Interventions
Licart™ (diclofenac epolamine) topical system
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
6 Years to 45 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Little Rock, Arkansas • La Palma, California • DeLand, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

"Beverage Hydration Index" of Commercial Therapeutic Beverages

NCT03262597
View directory record Official record
Conditions
Healthy
Interventions
enterade, Pedialyte, Gatorade, Water
Other
Lead sponsor
Sonoma State University
Other
Eligibility
18 Years to 35 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Rohnert Park, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 25, 2026, 8:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920
View directory record Official record
Conditions
Seborrheic Keratosis (SK)
Interventions
A-101 25%, A-101 32.5%, A-101 40%, A-101 Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 25, 2026, 8:16 PM EDT